ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Regenxbio Announces Pipeline Expansion with RGX-181
americanpharmaceuticalreview
August 31, 2018Regenxbio announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidas -
REGENXBIO to Develop New Product
contractpharma
August 31, 2018REGENXBIO?announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidas
Pharma Sources Insight January 2025
